Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Plastic and reconstructive surgeons consistently create large, raw surfaces as part of their
operative procedures. Thus, plastic & reconstructive surgery patients are among those at
highest risk for anticoagulant-associated bleeding adverse drug events (ADEs). This study
seeks to optimize both the safety and effectiveness of post-operative enoxaparin by comparing
aFXa levels, bleeding events, and VTE events among plastic & reconstructive surgery patients
randomized to receive two different enoxaparin dose regimens.